Related Experiment Video
Updated: Sep 24, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?
Gokay Nar1, Sanlialp Sara Cetin2, Rukiye Nar3
1Pamukkale University, Faculty of Medicine, Department of Cardiology, Denizli, Turkey.
Background:
Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However the relationship between FGF21 and coronary artery disease (CAD) is controversial This study was planned to investigate the role of FGF21 in CAD development and CAD severity.
Methods:
Seventy-eight patients with stable angina pectoris (SAP) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores.
Results:
FGF21 concentrations were found significantly higher in the SAP group than in the control group. [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. There was a negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026).
Conclusions:
The serum FGF21 levels are different between SAP and control patients. FGF21 is a marker for CAD diagnosis, but not for the evaluation of CAD severity.
More Related Videos
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome III: Diagnostic Studies
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

